CNBX Pharmaceuticals Statistics
Total Valuation
CNBX Pharmaceuticals has a market cap or net worth of 280,002. The enterprise value is 1.59 million.
| Market Cap | 280,002 |
| Enterprise Value | 1.59M |
Important Dates
The last earnings date was Monday, January 13, 2025.
| Earnings Date | Jan 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNBX Pharmaceuticals has 31.11 million shares outstanding. The number of shares has increased by 101.19% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 31.11M |
| Shares Change (YoY) | +101.19% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 3.26% |
| Float | 30.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.89 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.89 |
| EV / Sales | 39.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -34.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -136.71% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 20,319 |
| Profits Per Employee | -275,514 |
| Employee Count | 2 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.39% in the last 52 weeks. The beta is 0.79, so CNBX Pharmaceuticals's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -39.39% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 57.80 |
| Average Volume (20 Days) | 90,433 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.14 |
Income Statement
In the last 12 months, CNBX Pharmaceuticals had revenue of 40,637 and -551,027 in losses. Loss per share was -0.02.
| Revenue | 40,637 |
| Gross Profit | 40,637 |
| Operating Income | -448,077 |
| Pretax Income | -551,027 |
| Net Income | -551,027 |
| EBITDA | -397,138 |
| EBIT | -448,077 |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 17,339 in cash and 1.33 million in debt, giving a net cash position of -1.31 million or -0.04 per share.
| Cash & Cash Equivalents | 17,339 |
| Total Debt | 1.33M |
| Net Cash | -1.31M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -2.51M |
| Book Value Per Share | -0.08 |
| Working Capital | -2.51M |
Cash Flow
| Operating Cash Flow | -211,500 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,102.63% |
| Pretax Margin | -1,355.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNBX Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -101.19% |
| Shareholder Yield | -101.19% |
| Earnings Yield | -196.96% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 12, 2022. It was a reverse split with a ratio of 0.0083333.
| Last Split Date | May 12, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.0083333 |
Scores
CNBX Pharmaceuticals has an Altman Z-Score of -1767.88. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1767.88 |
| Piotroski F-Score | n/a |